Cargando…

Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

BACKGROUND: Predictive biomarkers are needed to identify oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER + /HER2-) metastatic breast cancer (MBC) patients who would likely benefit from cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine therapy. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Cheng, Hu, Shihui, Xu, Xiaoping, Zhang, Yongping, Wang, Biyun, Song, Shaoli, Yang, Zhongyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419349/ https://www.ncbi.nlm.nih.gov/pubmed/36028895 http://dx.doi.org/10.1186/s13058-022-01555-7

Ejemplares similares

The Preliminary Study of 16α-[18F]fluoroestradiol PET/CT in Assisting the Individualized Treatment Decisions of Breast Cancer Patients
por: Sun, Yifei, et al.
Publicado: (2015)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol
por: Jones, Ella F., et al.
Publicado: (2019)

Diagnostic and Prognostic Role of (18)F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept
por: Fiz, Francesco, et al.
Publicado: (2022)

Synthesis of Clinical-Grade [(18)F]-Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor-Targeting Therapeutic Drug
por: Dixit, Manish, et al.
Publicado: (2013)

Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy
por: van Kruchten, Michel, et al.
Publicado: (2015)

A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Gong, Chengcheng, et al.
Publicado: (2017)

18F-fluoroestradiol positron emission tomography in patients with breast cancer: a systematic review and meta-analysis
por: Matushita, Cristina S., et al.
Publicado: (2023)

Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer? ----A Pilot Study
por: Yang, Zhongyi, et al.
Publicado: (2013)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Zhao, Yannan, et al.
Publicado: (2018)

Quick Automatic Synthesis of Solvent-Free 16α-[(18)F] Fluoroestradiol: Comparison of Kryptofix 222 and Tetrabutylammonium Bicarbonate
por: Jiang, Xiao, et al.
Publicado: (2020)

Safety and Effectiveness of F-18 Fluoroestradiol Positron Emission Tomography/Computed Tomography: a Systematic Review and Meta-analysis
por: Mo, Jin A
Publicado: (2021)

Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer
por: Liu, Cheng, et al.
Publicado: (2020)

Comparison of (18)F-FES, (18)F-FDG, and (18)F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer
por: He, SiMin, et al.
Publicado: (2016)

Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer
por: Ivanidze, Jana, et al.
Publicado: (2021)

Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
por: Ma, Guang, et al.
Publicado: (2023)

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
por: Li, Yi, et al.
Publicado: (2021)

Total (18)F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
por: Fiebrich, Helle-Brit, et al.
Publicado: (2011)

The Added Value of (68)Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG–Negative Findings
por: Gu, Bingxin, et al.
Publicado: (2022)

Establishment and validation of a nomogram with intratumoral heterogeneity derived from (18)F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
por: Gu, Bingxin, et al.
Publicado: (2020)

Comparison of diagnostic sensitivity of [(18)F]fluoroestradiol and [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer
por: Chae, Sun Young, et al.
Publicado: (2020)

Prognostic Value of Heterogeneity Index Derived from Baseline (18)F-FDG PET/CT in Mantle Cell Lymphoma
por: Liu, Fei, et al.
Publicado: (2022)

The prognostic value of (18)F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients
por: Liu, Jun, et al.
Publicado: (2022)

Can (18)F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor-positive Breast Cancer Patient: A Prospective Comparative Study with (18)F-Fluorodeoxyglucose Positron Emission Tomography?
por: Gupta, Manoj, et al.
Publicado: (2017)

Impact of combined (18)F-FDG PET/CT in head and neck tumours
por: Syed, R, et al.
Publicado: (2005)

(18)F-FLT and (18)F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results
por: Qi, Shi, et al.
Publicado: (2017)

Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET
por: Cook, Gary J. R., et al.
Publicado: (2017)

The utility of (18)F-FDG PET/CT in brain tumours diagnosis
por: Pietrzak, Agata, et al.
Publicado: (2022)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging
por: Bao, Xiao, et al.
Publicado: (2016)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy
por: Malviya, Gaurav, et al.
Publicado: (2020)

Receiver operating characteristic (ROC) curve for classification of (18)F-NaF uptake on PET/CT
por: Valadares, Agnes Araujo, et al.
Publicado: (2016)

Heterogeneous uptake of (18)F-FDG and (18)F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
por: Hu, Yuan, et al.
Publicado: (2023)

Pretreatment (18) F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma——a retrospective study
por: Yang, Zhongyi, et al.
Publicado: (2015)

Posterior cortical atrophy phenotypic heterogeneity revealed by decoding (18)F-FDG-PET
por: Townley, Ryan A, et al.
Publicado: (2021)

Evaluation of hypoxia in an experimental rat tumour model by [(18)F]Fluoromisonidazole PET and immunohistochemistry
por: Dubois, L, et al.
Publicado: (2004)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0lqep4qb7qiupu8fochf0atou3